Business Context and Reporting Period
This Form 6-K filing by Evaxion Biotech A/S covers the month of January 2025. The report details a capital raise executed via an at-the-market (ATM) offering and the subsequent amendment to the Company's Articles of Association to reflect a share capital increase.
Key Financial Metrics
- Capital Raised: Approximately $4.85 million in net proceeds after fees and expenses.
- Shares Sold: 696,400 American Depositary Shares (ADSs).
- Average Sale Price: $7.1776 per ADS.
- Share Capital Increase: Nominal DKK 8,705,000, bringing the total nominal share capital to DKK 28,365,139.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for these operational metrics.
- Debt and Liquidity: The filing text does not provide a clear value for debt levels or overall liquidity positions beyond the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in share capital effective January 27, 2025, resulting from the issuance of 696,400 ADSs. This transaction was conducted under a Capital Demand Sales Agreement with Jones Trading Institutional Services LLC dated October 3, 2022.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies. The document is strictly a notification of the capital increase and the associated amendment to the Articles of Association.
Investor Verification Checklist
- Verify the total net proceeds of $4.85 million against the gross proceeds calculated from 696,400 ADSs at $7.1776.
- Confirm the updated nominal share capital of DKK 28,365,139 in the Danish Business Authority records.
- Review the attached Exhibit 1.1 (Amended Articles of Association) for any changes to shareholder rights or governance structures.
- Assess the impact of the dilution from the 696,400 new ADSs on existing shareholders.